{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T13:23:51Z","timestamp":1780838631541,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,6,24]],"date-time":"2014-06-24T00:00:00Z","timestamp":1403568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s12032-014-0074-9","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T10:42:44Z","timestamp":1403520164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study"],"prefix":"10.1007","volume":"31","author":[{"given":"Hasan","family":"Mutlu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyda","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halit","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"B\u00fcy\u00fck\u00e7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin Benderli","family":"Cihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd\u00fclsamet","family":"Erden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeki","family":"Akca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan \u015eenol","family":"Co\u015fkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,24]]},"reference":[{"key":"74_CR1","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.7314\/APJCP.2013.14.6.3887","volume":"14","author":"H Mutlu","year":"2013","unstructured":"Mutlu H, Buyukcelik A, Karaca H, Aksahin A, Berk V, Aslan T, Erden A, Akca Z, Ozkan M. Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study. Asian Pac J Cancer Prev. 2013;14:3887\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"74_CR2","unstructured":"Seer.cancer.gov\/csr\/2004_2008\/results."},{"key":"74_CR3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"74_CR4","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP Meerbeeck van","year":"2005","unstructured":"van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G. European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881\u20139.","journal-title":"J Clin Oncol"},{"key":"74_CR5","first-page":"70","volume":"12","author":"FE Mott","year":"2012","unstructured":"Mott FE. Mesothelioma: a review. Ochsner J. 2012;12:70\u20139.","journal-title":"Ochsner J"},{"key":"74_CR6","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","volume":"26","author":"J Jassem","year":"2008","unstructured":"Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698\u2013704.","journal-title":"J Clin Oncol"},{"key":"74_CR7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/030089160509100104","volume":"91","author":"L Portalone","year":"2005","unstructured":"Portalone L, Antilli A, Nunziati F, Crispino C, de Marinis F, Friggeri L, Lombardi A, Lorusso V, Pronzato P, Sambiasi D, et al. Associazione Italiana pneumologi ospedalieri thoracic oncology study group. Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. Tumori. 2005;91:15\u20138.","journal-title":"Tumori"},{"key":"74_CR8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.lungcan.2006.04.014","volume":"53","author":"G Utkan","year":"2006","unstructured":"Utkan G, B\u00fcy\u00fck\u00e7elik A, Yal\u00e7in B, Akbulut H, Demirkazik A, Din\u00e7ol D, Onur H, G\u00f6ren D, Mousa U, Senler FC, et al. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer. 2006;53:367\u201374.","journal-title":"Lung Cancer"},{"key":"74_CR9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2007.09.018","volume":"60","author":"SR Kalmadi","year":"2008","unstructured":"Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer. 2008;60:259\u201363.","journal-title":"Lung Cancer"},{"key":"74_CR10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.bjc.6600505","volume":"87","author":"AK Nowak","year":"2002","unstructured":"Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491.","journal-title":"Br J Cancer"},{"key":"74_CR11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.coc.0000144852.75613.56","volume":"28","author":"B Castagneto","year":"2005","unstructured":"Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, Botta M, Sinaccio G. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol. 2005;28:223.","journal-title":"Am J Clin Oncol"},{"key":"74_CR12","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","volume":"30","author":"HL Kindler","year":"2012","unstructured":"Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, J\u00e4nne PA, Quinn DI, Koczywas MN, Brahmer JR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of\u00a0gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant\u00a0mesothelioma. J Clin Oncol. 2012;30:2509\u201315.","journal-title":"J Clin Oncol"},{"key":"74_CR13","volume-title":"AJCC cancer staging manual","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.","edition":"7"},{"key":"74_CR14","doi-asserted-by":"crossref","unstructured":"Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, et al. Gemcitabine and vinorelbine as\u00a0second-line\u00a0or beyond treatment in patients with\u00a0malignant\u00a0pleural mesothelioma\u00a0pretreated with platinum plus pemetrexed\u00a0chemotherapy. Int J Clin Oncol. 2013. doi: 10.1007\/s10147-013-0619-5 .","DOI":"10.1007\/s10147-013-0619-5"},{"key":"74_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pneumo.2010.07.013","volume":"66","author":"J Margery","year":"2010","unstructured":"Margery J, Rivi\u00e8re F, Planchard D, Le Floch H, Ferrand FR, Mairovitz A, Besse B, Vaylet F, Ruffi\u00e9 P. Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005\u20132006). Rev Pneumol Clin. 2010;66:255\u20139.","journal-title":"Rev Pneumol Clin"},{"key":"74_CR16","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","volume":"112","author":"PA Zucali","year":"2008","unstructured":"Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A. Gemcitabine\u00a0and vinorelbine in pemetrexed-pretreated patients with\u00a0malignant\u00a0pleural mesothelioma. Cancer. 2008;112:1555\u201361.","journal-title":"Cancer"},{"key":"74_CR17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/COC.0b013e3181cae90e","volume":"34","author":"I Tourkantonis","year":"2011","unstructured":"Tourkantonis I, Makrilia N, Ralli M, Alamara C, Nikolaidis I, Tsimpoukis S, Charpidou A, Kotanidou A, Syrigos K. Phase II study of\u00a0gemcitabine\u00a0plus docetaxel as second-line treatment in\u00a0malignant\u00a0pleural mesothelioma: a single institution study. Am J Clin Oncol. 2011;34:38\u201342.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"74_CR18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1745-6673-3-34","volume":"18","author":"A Xanthopoulos","year":"2008","unstructured":"Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Sch\u00f6nfeld N, Serke M. Gemcitabine\u00a0combined with oxaliplatin in pretreated patients with\u00a0malignant\u00a0pleural mesothelioma: an observational study. J Occup Med Toxicol. 2008;18(3):34.","journal-title":"J Occup Med Toxicol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-014-0074-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0074-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T20:35:31Z","timestamp":1565555731000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-014-0074-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,24]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1007\/s12032-014-0074-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,24]]},"article-number":"74"}}